Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Advances in the Pharmacology of Gynecological Cancer
share announcement

Advances in the Pharmacology of Gynecological Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: closed (5 March 2021) | Viewed by 2501

Special Issue Editor

Prof. Judith A. Smith

E-Mail Website
Guest Editor
Department of Obstetrics, Gynecology & Reproductive Sciences, UTHealth McGovern Medical School, 6431 Fannin Street, Rm 3.152, Houston, TX 77030, USA
Interests: HPV; mechanisms of resistance; PARP inhibitors; carboplatin; integrative medicine

Special Issue Information

Dear Colleagues,

In the past ten years, there have been significant advances in the pharmacological management of ovarian, endometrial and cervical cancer.  This has been driven by the availability of tumor genetic testing to identify actionable targets, the optimization of routes, sequences, and/or the frequency of chemotherapy delivery, and the modulation of drug resistance.
This Special Issue will focus on the recent advancements in the management of ovarian, endometrial, and cervical cancer, including PARP inhibitors, immunotherapy, targeted therapies and the optimization of traditional chemotherapy regimens based on routes of administration (i.e., IP therapy or hyperthermic chemotherapy).
We are looking for bench-to-bedside research studies and clinical case reports that identify new advancements in the pharmacological management of gynecologic malignancies.

We are looking for cases reports, original research, and clinical controversaries.

Prof. Judith A. Smith
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecologic cancers
  • pharmacology
  • PARP inhibitors
  • immunotherapy
  • targeted therapies

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

16 pages, 246 KiB  
Review
Current Status and Prospects of Immunotherapy for Gynecologic Melanoma
by Mayuka Anko, Yusuke Kobayashi, Kouji Banno and Daisuke Aoki
J. Pers. Med. 2021, 11(5), 403; https://doi.org/10.3390/jpm11050403 - 12 May 2021
Cited by 4 | Viewed by 2232
Abstract
Gynecologic melanomas are rare and have a poor prognosis. Although immunotherapy (immune checkpoint inhibitors) and targeted therapy has greatly improved the systemic treatment of cutaneous melanoma (CM) in recent years, its efficacy in gynecologic melanomas remains uncertain because of the rarity of this malignancy [...] Read more.
Gynecologic melanomas are rare and have a poor prognosis. Although immunotherapy (immune checkpoint inhibitors) and targeted therapy has greatly improved the systemic treatment of cutaneous melanoma (CM) in recent years, its efficacy in gynecologic melanomas remains uncertain because of the rarity of this malignancy and its scarce literature. This review aimed to evaluate the literature of gynecologic melanomas treated with immunotherapy and targeted therapy through a PubMed search. We identified one study focusing on the overall survival of gynecologic melanomas separately and five case series and nine case reports concentrating on gynecologic melanomas treated with an immune checkpoint inhibitor and/or targeted therapy. Furthermore, the KIT mutation has the highest rate among all mutations in mucosal melanoma types. The KIT inhibitors (Tyrosine kinase inhibitors: TKIs) imatinib and nilotinib could be the treatment options. Moreover, immune checkpoint inhibitors combined with KIT inhibitors may potentially treat cases of resistance to immune checkpoint inhibitors. However, because of the different conditions and a small number of cases, it is difficult to evaluate the efficacy of immunotherapy and targeted therapy for gynecologic melanoma rigorously at this time. Further prospective cohort or randomized trials of gynecologic melanoma alone are needed to assess the treatment with solid evidence. Full article
(This article belongs to the Special Issue Advances in the Pharmacology of Gynecological Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop